MedTrace Logo

DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

NCT00640965 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-05-05

No results posted yet for this study

Summary

The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.

Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.

Conditions

Interventions

DRUG

DP-VPA

DP-VPA dose escalation to 900mg, then continued for 8 weeks

DRUG

DP-VPA Placebo

Matching Placebo to Active, dose escalation, then continued for 8 weeks

Sponsors & Collaborators

  • D-Pharm Ltd.

    lead INDUSTRY

Principal Investigators

  • Gilad Rosenberg, M.D. · D-Pharm Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-06-30
Completion
2009-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640965 on ClinicalTrials.gov